# Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy

> **NCT05929651** · PHASE4 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 71 (actual)

## Conditions studied

- Meningococcal Immunisation
- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** MenACYW conjugate vaccine

## Key facts

- **NCT ID:** NCT05929651
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-07
- **Primary completion:** 2024-09-09
- **Final completion:** 2024-09-09
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05929651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05929651, "Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05929651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*